Exclusive Summary

• Backed by highly authoritative US-FDA and PIC/S dual GMP certifications, serving as a catalyst for local distributors to achieve accelerated regulatory approvals across highly regulated and semi-regulated markets.
• Patents are entirely expired; as the universally recognized first-line standard of care for postmenopausal Hormone Replacement Therapy (HRT), the market requires zero clinical education, ensuring immediate commercial off-take.
• Sustained by a monumental and resilient market demand, targeting an estimated 1.2 billion menopausal women globally by 2030, synergized by the fast-growing, long-term niche of male-to-female (MtF) transgender hormone therapy.
• Empowered by China's robust API-to-finished-dose manufacturing ecosystem, offering unparalleled cost efficiencies and supply chain shielding compared to typical Western generic competitors, maximizing distributor margins.